• Featured Product
  • KD/KO验证

CoraLite®594-conjugated CDR2L Monoclonal antibody

CDR2L Monoclonal Antibody for IF/ICC
Cat No. CL594-66791

产品说明书

CloneNo. 2E12D10

宿主/亚型

Mouse / IgG1

种属反应性

Human, Mouse, Rat

应用

IF/ICC

CDR2L, HUMPPA, Paraneoplastic 62 kDa antigen

缓冲液配方:  PBS and Azide
PBS and Azide
规格: 

-/ -


经过测试的应用

Positive IF/ICC detected inHEK-293 cells
Planning an IHC experiment? We recommend our IHCeasy CDR2L Ready-To-Use IHC Kit. CDR2L primary antibody included.
For other applications, we recommend the unconjugated version of this antibody, 66791-1-Ig

推荐稀释比

应用推荐稀释比
Immunofluorescence (IF)/ICCIF/ICC : 1:50-1:500
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

产品信息

CL594-66791 targets CDR2L in IF/ICC applications and shows reactivity with Human, Mouse, Rat samples.

经测试应用 IF/ICC Application Description
经测试反应性 Human, Mouse, Rat
免疫原 CDR2L fusion protein Ag6139 种属同源性预测
宿主/亚型 Mouse / IgG1
抗体类别 Monoclonal
产品类型 Antibody
全称 cerebellar degeneration-related protein 2-like
别名 CDR2L, HUMPPA, Paraneoplastic 62 kDa antigen
计算分子量 53 kDa
观测分子量 54 kDa
GenBank蛋白编号BC047534
基因名称 CDR2L
Gene ID (NCBI) 30850
RRIDAB_2920039
偶联类型 CoraLite®594 Fluorescent Dye
最大激发/发射波长588 nm / 604 nm
形式 Liquid
纯化方式Protein G purification
UNIPROT IDQ86X02
储存缓冲液 PBS with 50% glycerol, 0.05% Proclin300, 0.5% BSA , pH 7.3
储存条件Store at -20°C. Avoid exposure to light. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

背景介绍

Cerebellar degeneration-related protein 2-like(CDR2L), also named as HUMPPA or Paraneoplastic 62 kDa antigen, is a 465 amino acid protein, which belongs to the CDR2 family. CDR2L contains three potential coiled-coil regions. The functions of protein is so far not known. CDR2L is expressed in the brain and localizes in the cytoplasm.

实验方案

Product Specific Protocols
IF protocol for CL594 CDR2L antibody CL594-66791Download protocol
Standard Protocols
Click here to view our Standard Protocols
Loading...